Public record
Vyvanse: the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Medicaid
Medicaid prescriptions for Vyvanse by state
State Medicaid programmes paid for 2,882,766 Vyvanse prescriptions in 2025, with $1.08B reimbursed before rebates. Wisconsin reported the most (253,366), followed by Ohio (231,566) and California (196,518); 51 states and territories reported any.
| Measure | Value | Note |
|---|---|---|
| Prescriptions paid by Medicaid, 2025 | 2,882,766 | |
| Total reimbursed before rebates, 2025 | $1.08B | |
| States and territories reporting | 51 | with at least one count CMS did not suppress |
| Wisconsin | 253,366 prescriptions | $101.3M reimbursed |
| Ohio | 231,566 prescriptions | $85.7M reimbursed |
| California | 196,518 prescriptions | $77.1M reimbursed |
| North Carolina | 191,662 prescriptions | $72.5M reimbursed |
| New York | 142,798 prescriptions | $55.7M reimbursed |
How this was calculated
Matched each Medicaid product code to the FDA NDC Directory by labeler and product code, kept finished single-ingredient products, then summed prescriptions and reimbursement by state. National roll-up and suppressed rows dropped.
Vyvanse only (brand-name lisdexamfetamine), fee-for-service and managed care, 2025
Counts under 11 are suppressed by CMS and left out, so totals are a floor. Amounts are before rebates. Differences between states reflect programme size and coverage rules. Compounded products are not included.
Pharmacy cost
Pharmacy acquisition cost (NADAC) for Vyvanse
Retail pharmacies paid an average of $12.35 per unit for VYVANSE 10 MG CAPSULE as of 2026-11-11, compared with $12.35 twelve months earlier (-0.1%). This is a pharmacy purchase cost, not a patient price.
| Measure | Value | Note |
|---|---|---|
| VYVANSE 10 MG CAPSULE | $12.35 per unit | 12 months earlier $12.35 (-0.1%) |
| VYVANSE 10 MG CHEWABLE TABLET | $12.35 per unit | 12 months earlier $12.35 (+0.1%) |
| VYVANSE 20 MG CAPSULE | $12.35 per unit | 12 months earlier $12.36 (-0.1%) |
| VYVANSE 20 MG CHEWABLE TABLET | $12.34 per unit | 12 months earlier $12.36 (-0.1%) |
| VYVANSE 30 MG CAPSULE | $12.34 per unit | 12 months earlier $12.38 (-0.3%) |
| VYVANSE 30 MG CHEWABLE TABLET | $12.35 per unit | 12 months earlier $12.37 (-0.2%) |
How this was calculated
Matched NADAC product codes to the FDA NDC Directory, kept finished single-ingredient products, and listed the product descriptions with the most package codes. The earlier price is the same package code in the file one year before.
Vyvanse (brand-name lisdexamfetamine) in the weekly NADAC file of 2026-11-11, compared with the file of 2025-11-12
NADAC is the average invoice price retail pharmacies pay, from a voluntary survey. It leaves out rebates, dispensing fees and markups, and it is not what a patient or insurer pays. Compounded products are not surveyed.
Articles on Vyvanse
- Does Aetna (CVS Health) Cover Vyvanse? Prior Authorization, Formulary Tier, and Appeal Steps
- Does Blue Cross Blue Shield (Federated) Cover Vyvanse?
- Does Kaiser Permanente Cover Vyvanse? Formulary, Prior Auth, and Appeal Steps
- Does UnitedHealthcare Cover Vyvanse? Formulary Tier, Prior Authorization, and Appeal Steps
- U.S. Vyvanse Manufacturer Savings: Check the Current Offer
- Does Highmark Cover Vyvanse? Formulary Tiers, Prior Auth, and Cost-Saving Options